


### Listing of Claims:

- 
- Chemical structure IV is a complex molecule featuring a central indole ring system. The indole ring is substituted with R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, and R<sup>6</sup>. It is connected via a linker (X) to a chain of repeating units (D), (a), (m), and (n). The chain is terminated by a group W. The indole ring is also connected to a side chain containing a carbonyl group and an ester linkage to R<sup>14</sup>. The side chain includes repeating units (j) and (k) and is terminated by R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, and R<sup>13</sup>.

Page 2 of 19

dialkylaminoalkyl, alkanoyl; monoalkylamino; dialkylamino; aminoalkyl; monoalkylaminoalkyl; dialkylaminoalkyl; alkanoyl; heteroaryl having 5-14 ring members, optionally substituted with one or more of halogen, hydroxy, cyano, alkyl, aryl, alkoxy, haloalkyl, arylalkyl, arylalkoxy, aryloxy, alkylsulfonyl, alkylsulfinyl, alkylalkoxyaryl, monoalkylamino, dialkylamino, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkanoyl; or



wherein  $R^{17}$  and  $R^{18}$  together form  $-\text{CH}_2\text{CH}_2-\text{O}-$ ,  $-\text{O}-\text{CH}_2\text{CH}_2-$ ,  $-\text{O}-\text{CH}_2-\text{O}-$  or  $-\text{O}-\text{CH}_2\text{CH}_2-\text{O}-$ ; or  $R^{10}$  and  $R^{12}$  are taken together to form  $-(\text{CH}_2)_s-$ , wherein  $s$  is 0 (a bond) or 1 to 4, while  $R^{11}$  and  $R^{13}$  are as defined as above; or  $R^{10}$  and  $R^{12}$  are taken together to form a double bond when  $i$  is 0 and  $k$  is 1, while  $R^{11}$  and  $R^{13}$  are as defined above; or  $R^{10}$  and  $R^{11}$  are taken together to form  $-(\text{CH}_2)_t-$ , wherein  $t$  is 2 to 8, while  $R^{12}$  and  $R^{13}$  are as defined as above, or  $R^{12}$  and  $R^{13}$  are taken together to form  $-(\text{CH}_2)_u-$  wherein  $u$  is 2 to 8, while  $R^{10}$  and  $R^{11}$  are as defined as above;


$i$  is from 0 to 4;

$j$  is from 0 to 4;

$k$  is 0 or 1;

$R^{14}$  is hydrogen, ~~or a functionality that acts as a prodrug, including~~ alkyl, aryl, aralkyl, dialkylaminoalkyl, 1-morpholinoalkyl, 1-piperidinylalkyl, pyridinylalkyl, alkoxy(alkoxy)alkoxyalkyl, or (alkoxycarbonyl)oxyethyl;

W is:



wherein:

$R^{16}$  is hydrogen, alkyl, haloalkyl or halogen; and

$R^{27}$ ,  $R^{28}$ , and  $R^{29}$  are independently hydrogen, halogen, alkyl, alkoxy or aryl.

2. (Original) The compound of claim 1, wherein  $R^{14}$  is a prodrug, selected from the group consisting of: alkyl, aryl, aralkyl, dialkylaminoalkyl, 1-morpholinoalkyl, 1-piperidinylalkyl, pyridinylalkyl, alkoxy(alkoxy) alkoxyalkyl, or (alkoxycarbonyl)oxyethyl.

3. (Previously Presented) The compound of claim 1, wherein:

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  independently represent hydrogen, halogen,  $(C_{1-8})$ alkyl,  $(C_{6-10})$ aryl,  $(C_{6-10})$ ar $(C_{1-8})$ alkyl, 5-14 member heteroaryl, or 5-14 member heteroaryl $(C_{1-8})$ alkyl;

$R^6$ ,  $R^7$ ,  $R^8$  and  $R^9$  independently represent hydrogen,  $(C_{1-8})$ alkyl, hydroxy $(C_{1-8})$ alkyl, amino $(C_{1-8})$ alkyl, mono $(C_{1-8})$ alkylamino $(C_{1-8})$ alkyl, di $(C_{1-8})$ alkylamino $(C_{1-8})$ alkyl, carboxy $(C_{1-8})$ alkyl,  $(C_{6-10})$ aryl or  $(C_{6-10})$ ar $(C_{1-8})$ alkyl;

or  $R^6$  and  $R^7$  are taken together to form  $-(CH_2)_p-$ , where p is 2-8, while  $R^8$  and  $R^9$  are defined as above; or  $R^8$  and  $R^9$  are taken together to form  $-(CH_2)_q-$ , where q is 2-8, while  $R^6$  and  $R^7$  are defined as above; or  $R^6$  and  $R^8$  are taken together to form  $-(CH_2)_r-$ , while r is zero (a bond), 1 or 2, while  $R^7$  and  $R^9$  are defined as above;

X represents oxygen, sulfur,  $-CH_2-$ ,  $-NH-$ ,  $-(C=O)NH-$  or  $-NH(C=O)-$ ;

n is from 0 to 4;

m is from 0 to 4;


a is from 0 or 1;

D represents oxygen;

v is from 0 or 1;

$R^{10}$ ,  $R^{11}$ ,  $R^{12}$  and  $R^{13}$  independently represent: hydrogen; hydroxy;  $(C_{1-8})$ alkyl;  $(C_{1-8})$ alkoxy;  $(C_{3-8})$ cycloalkyl;  $(C_{6-10})$ aryl, optionally substituted with one or more of halogen, hydroxy, cyano,  $(C_{1-8})$ alkyl,  $(C_{6-10})$ aryl,  $(C_{1-8})$ alkoxy, halo $(C_{1-8})$ alkyl,  $(C_{6-10})$ aryl $(C_{1-8})$ alkyl,  $(C_{6-10})$ aryl $(C_{1-8})$ alkoxy,  $(C_{6-10})$ aryloxy,  $(C_{1-8})$ alkylsulfonyl,  $(C_{1-8})$ alkylsulfinyl,  $(C_{1-8})$ alkoxy $(C_{6-10})$ aryl $(C_{1-8})$ alkyl, mono $(C_{1-8})$ alkylamino, di $(C_{1-8})$ alkylamino, amino $(C_{1-8})$ alkyl, mono $(C_{1-8})$ alkylamino $(C_{1-8})$ alkyl, di $(C_{1-8})$ alkylamino $(C_{1-8})$ alkyl,  $(C_{1-8})$ alkanoyl; mono $(C_{1-8})$ alkylamino; di $(C_{1-8})$ alkylamino; amino $(C_{1-8})$ alkyl; mono $(C_{1-8})$ alkylamino $(C_{1-8})$ alkyl; di $(C_{1-8})$ alkylamino $(C_{1-8})$ alkyl;  $(C_{1-8})$ alkanoyl; heteroaryl having 5-14 ring members, optionally substituted with one or more of halogen, hydroxy, cyano,  $(C_{1-8})$ alkyl,  $(C_{6-10})$ aryl,  $(C_{1-8})$ alkyl,

$\text{g}$ )alkoxy, halo( $\text{C}_{1-8}$ )alkyl, ( $\text{C}_{6-10}$ )aryl( $\text{C}_{1-8}$ )alkyl, ( $\text{C}_{6-10}$ )aryl( $\text{C}_{1-8}$ )alkoxy, ( $\text{C}_{6-10}$ )aryloxy, ( $\text{C}_{1-8}$ )alkylsulfonyl, ( $\text{C}_{1-8}$ )alkylsulfinyl, ( $\text{C}_{1-8}$ )alkoxy( $\text{C}_{6-10}$ )aryl( $\text{C}_{1-8}$ )alkyl, mono( $\text{C}_{1-8}$ )alkylamino, di( $\text{C}_{1-8}$ )alkylamino, amino( $\text{C}_{1-8}$ )alkyl, mono( $\text{C}_{1-8}$ )alkylamino( $\text{C}_{1-8}$ )alkyl, di( $\text{C}_{1-8}$ )alkylamino( $\text{C}_{1-8}$ )alkyl, ( $\text{C}_{1-8}$ )alkanoyl; or



wherein  $\text{R}^{17}$  and  $\text{R}^{18}$  together form  $-\text{CH}_2\text{CH}_2-\text{O}-$ ,  $-\text{O}-\text{CH}_2\text{CH}_2-$ ,  $-\text{O}-\text{CH}_2-\text{O}-$  or  $-\text{O}-\text{CH}_2\text{CH}_2-\text{O}-$ ; or  $\text{R}^{10}$  and  $\text{R}^{12}$  are taken together to form  $-(\text{CH}_2)_s-$ , wherein  $s$  is 0 (a bond) or 1 to 4, while  $\text{R}^{11}$  and  $\text{R}^{13}$  are as defined as above; or  $\text{R}^{10}$  and  $\text{R}^{12}$  are taken together to form a double bond when  $i$  is 0 and  $k$  is 1, while  $\text{R}^{11}$  and  $\text{R}^{13}$  are as defined above; or  $\text{R}^{10}$  and  $\text{R}^{11}$  are taken together to form  $-(\text{CH}_2)_t-$ , wherein  $t$  is 2 to 8, while  $\text{R}^{12}$  and  $\text{R}^{13}$  are as defined as above, or  $\text{R}^{12}$  and  $\text{R}^{13}$  are taken together to form  $-(\text{CH}_2)_u-$  wherein  $u$  is 2 to 8, while  $\text{R}^{10}$  and  $\text{R}^{11}$  are as defined as above; or


$i$  is from 0 to 4;

$j$  is from 0 to 4; and

$k$  is 0 or 1;

$\text{R}^{14}$  is hydrogen or a functionality that acts as a prodrug;

$\text{W}$  is:




wherein:

$\text{R}^{16}$  is hydrogen, ( $\text{C}_{1-8}$ )alkyl, halo( $\text{C}_{1-8}$ )alkyl or halogen;

$\text{R}^{27}$ ,  $\text{R}^{28}$ , and  $\text{R}^{29}$  are independently hydrogen, halogen, ( $\text{C}_{1-8}$ )alkyl, ( $\text{C}_{1-8}$ )alkoxy, or ( $\text{C}_{6-10}$ )aryl.


4. (Original) The compound of claim 1, wherein  $R^1$  and  $R^2$  independently represent hydrogen, halogen,  $(C_{1-6})$ alkyl,  $(C_{6-10})$ aryl,  $(C_{6-10})$ ar $(C_{1-6})$ alkyl, 5-14 member heteroaryl, or 5-14 member heteroaryl $(C_{1-8})$ alkyl.
5. (Original) The compound of claim 4, wherein  $R^1$  and  $R^2$  independently represent hydrogen, methyl, ethyl, propyl, butyl, phenyl, benzyl or phenylethyl.
6. (Original) The compound of claim 5, wherein  $R^1$  and  $R^2$  independently represent hydrogen, methyl, ethyl or propyl.
7. (Original) The compound of claim 1, wherein  $R^3$ ,  $R^4$  and  $R^5$  independently represent hydrogen,  $(C_{1-6})$ alkyl,  $(C_{6-10})$ aryl, or  $(C_{6-10})$ ar $(C_{1-6})$ alkyl.
8. (Original) The compound of claim 7, wherein  $R^3$ ,  $R^4$  and  $R^5$  are hydrogen or  $(C_{1-4})$ alkyl.
9. (Original) The compound of claim 1, wherein  $R^6$ ,  $R^7$ ,  $R^8$  and  $R^9$  independently represent hydrogen, halogen or  $(C_{1-6})$ alkyl.
10. (Original) The compound of claim 1, wherein X is oxygen,  $-CH_2-$  or  $-(C=O)NH-$ .
11. (Original) The compound of claim 10, wherein X is oxygen or  $-CH_2-$ .
12. (Previously Presented) The compound of claim 1, wherein W is:



wherein:

- $R^{16}$  is hydrogen,  $(C_{1-8})$ alkyl, halo $(C_{1-8})$ alkyl or halogen; and  
 $R^{27}$ ,  $R^{28}$ , and  $R^{29}$  are hydrogen, halogen,  $(C_{1-8})$ alkyl,  $(C_{1-8})$ alkoxy, or  $(C_{6-10})$ aryl.

13. (Previously Presented) The compound of claim 1, wherein W is




wherein:

R<sup>16</sup> is hydrogen, (C<sub>1-8</sub>)alkyl, halo(C<sub>1-8</sub>)alkyl or halogen; and


R<sup>27</sup>, R<sup>28</sup>, and R<sup>29</sup> are hydrogen, halogen, (C<sub>1-8</sub>)alkyl, (C<sub>1-8</sub>)alkoxy, or (C<sub>6-10</sub>)aryl.

14. (Previously Presented) The compound of claim 13, wherein W is




15. (Original) The compound of claim 1, wherein R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup> and R<sup>13</sup> independently represent: hydrogen; hydroxy, (C<sub>1-12</sub>)alkyl; (C<sub>3-6</sub>)cycloalkyl; or (C<sub>6-10</sub>)aryl, optionally substituted with one or more of halogen, hydroxy, cyano, (C<sub>1-8</sub>)alkyl, (C<sub>6-10</sub>)aryl, (C<sub>1-8</sub>)alkoxy, halo(C<sub>1-8</sub>)alkyl, (C<sub>6-10</sub>)aryl(C<sub>1-8</sub>)alkyl, (C<sub>6-10</sub>)aryl(C<sub>1-8</sub>)alkoxy, or (C<sub>6-10</sub>)aryloxy.

16. (Original) The compound of claim 1, wherein R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup> and R<sup>13</sup> independently represent a heteroaryl having 5-14 ring members, optionally substituted with one or more of halogen, hydroxy, cyano, (C<sub>1-8</sub>)alkyl, (C<sub>1-8</sub>)alkoxy(C<sub>6-10</sub>)aryl, (C<sub>1-8</sub>)alkoxy, halo(C<sub>1-8</sub>)alkyl, (C<sub>6-10</sub>)aryl(C<sub>1-8</sub>)alkyl, (C<sub>6-10</sub>)aryl(C<sub>1-8</sub>)alkoxy, (C<sub>6-10</sub>)aryloxy, (C<sub>1-8</sub>)alkylsulfonyl, (C<sub>1-8</sub>)alkylsulfinyl, (C<sub>1-8</sub>)alkylamino, (C<sub>1-8</sub>)alkylamino(C<sub>1-8</sub>)alkyl, di(C<sub>1-8</sub>)alkylamino, di(C<sub>1-8</sub>)alkylamino(C<sub>1-8</sub>)alkyl, or carboxy(C<sub>1-8</sub>)alkyl; or



wherein  $R^{17}$  and  $R^{18}$  together form  $-\text{CH}_2\text{CH}_2-\text{O}-$ ,  $-\text{O}-\text{CH}_2\text{CH}_2-$ ,  $-\text{O}-\text{CH}_2-\text{O}-$  or  $-\text{O}-\text{CH}_2\text{CH}_2-\text{O}-$ .

17. (Original) The compound of claim 1, wherein  $R^{12}$  and  $R^{13}$  are independently thiazolyl, benzofuranyl,



wherein:

b is from 0 to 4;

$R^{32}$  is halogen,  $(\text{C}_{1-6})$ alkyl, halo $(\text{C}_{1-6})$ alkyl,  $(\text{C}_{1-6})$ alkoxy,

$(\text{C}_{1-6})$ alkoxy $(\text{C}_{1-6})$ alkyl or halo $(\text{C}_{1-6})$ alkoxy;

$R^{33}$  is halogen; and

$R^{34}$  is  $(\text{C}_{1-6})$ alkyl, hydroxy or  $(\text{C}_{1-6})$ alkoxy, or


two of  $R^{32}$ , or two of  $R^{33}$ , or one of  $R^{33}$  and  $R^{34}$ , when attached to adjacent carbon atoms, may together form a ring, wherein the ring formed is an aliphatic, aryl or heteroaryl ring, each of which may be optionally substituted by one or more of halogen, hydroxy, cyano, alkyl, aryl, alkoxy, haloalkyl, arylalkyl, arylalkoxy, aryloxy, alkylsulfonyl, alkylsulfinyl, alkoxyarylalkyl, monoalkylamino, dialkylamino, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkanoyl; monoalkylamino; dialkylamino; aminoalkyl; monoalkylaminoalkyl; dialkylaminoalkyl; alkanoyl.

18. (Original) The compound of claim 1, wherein  $R^{10}$  and  $R^{12}$  are taken together to form a double bond where i is 0 and k is 1, and  $R^{11}$  and  $R^{13}$  are each hydrogen.

19. (Original) The compound of claim 1, wherein  $R^{10}$  is an optionally substituted aryl or an optionally substituted heteroaryl.

20. (Original) The compound of claim 1, wherein i and j are each 0.

21. (Original) The compound of claim 1, wherein k is 1.
22. (Original) The compound of claim 1, wherein R<sup>14</sup> is hydrogen.
23. (Original) The compound of claim 1, wherein i and j are each zero; k is one; R<sup>10</sup>, R<sup>11</sup> and R<sup>12</sup> are each hydrogen; and R<sup>13</sup> is hydrogen, (C<sub>1-6</sub>)alkyl, (C<sub>6-10</sub>)aryl or (C<sub>6-10</sub>)ar(C<sub>1-4</sub>)alkyl.
24. (Previously Presented) The compound of claim 1, wherein:
- R<sup>1</sup> is hydrogen or (C<sub>1-4</sub>)alkyl;
  - R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, and R<sup>5</sup> are hydrogen or (C<sub>1-4</sub>)alkyl;
  - R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> and R<sup>9</sup> are hydrogen or (C<sub>1-4</sub>)alkyl;
  - X is oxygen or -CH<sub>2</sub>-;
  - n is 0 or 1;
  - m is 0 or 1;
  - R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup> and R<sup>13</sup> independently represent hydrogen, (C<sub>1-6</sub>)alkyl or (C<sub>6-10</sub>)ar(C<sub>1-6</sub>)alkyl; or
  - one of the combination R<sup>10</sup> and R<sup>11</sup>, R<sup>12</sup> and R<sup>13</sup> or R<sup>10</sup> and R<sup>12</sup> are taken together to form -(CH<sub>2</sub>)<sub>s</sub>-, wherein s is 1 or 2 while the remaining of R<sup>10</sup>-R<sup>13</sup> are as defined above;
  - i is 0 or 1;
  - j is 0 or 1;
  - k is 0 or 1;
  - R<sup>14</sup> is hydrogen, C<sub>1-6</sub> alkyl or benzyl;
  - W is:



wherein:

- R<sup>16</sup> is hydrogen, (C<sub>1-8</sub>)alkyl, halo(C<sub>1-8</sub>)alkyl or halogen; and
- R<sup>27</sup>, R<sup>28</sup>, and R<sup>29</sup> are hydrogen, halogen, (C<sub>1-8</sub>)alkyl, (C<sub>1-8</sub>)alkoxy, or (C<sub>6-10</sub>)aryl.



25. (Original) The compound of claim 24, wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$  and  $R^{14}$  are hydrogen.

26. (Original) The compound of claim 1, wherein  $R^{10}$  and  $R^{11}$  are taken together to form -  $(CH_2)_t$ -, where t is 2 to 5 and  $R^{12}$  and  $R^{13}$  are each hydrogen.

27. (Original) The compound of claim 1, wherein  $R^{12}$  and  $R^{13}$  are taken together to form -  $(CH_2)_u$ -, where u is 2 to 5 and  $R^{10}$  and  $R^{11}$  are each hydrogen.

28. (Original) The compound of claim 1, wherein  $R^{10}$  and  $R^{12}$  are taken together to form -  $(CH_2)_s$ - where s is zero or 1 to 4, and  $R^{11}$  and  $R^{13}$  are each hydrogen.

29. (Original) The compound of claim 1, wherein:

X is  $-(C=O)NH-$ ;

n, m, a and v are each 0; and

$R^6$ ,  $R^7$ ,  $R^{12}$  and  $R^{13}$  are hydrogen.

30. (Original) The compound of claim 1, wherein:

X is oxygen;

n and m are each 0;

a and v are each 1;

D is oxygen;

$R^6$ ,  $R^7$ ,  $R^8$  and  $R^9$  are hydrogen.

31. (Original) The compound of claim 1, wherein:

X is oxygen;

n, m and v are each 0;

a is 1; and

$R^6$ ,  $R^7$ ,  $R^{12}$  and  $R^{13}$  are hydrogen.

32. (Original) The compound of claim 1, wherein:

X is  $-\text{CH}_2-$ ;

n, m and v are each 0;

a is 1; and

$\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^{12}$  and  $\text{R}^{13}$  are hydrogen.

33. (Original) The compound of claim 1, wherein v is 0.

34. (Previously Presented) The compound of claim 1, wherein

$\text{R}^1$  is hydrogen or  $-\text{CH}_3$ ;

$\text{R}^2$ ,  $\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$  and  $\text{R}^9$  are hydrogen;

X is oxygen or  $-\text{CH}_2-$ ;

n is 0 or 1;

m is 0 or 1;

$\text{R}^{10}$ ,  $\text{R}^{11}$ ,  $\text{R}^{12}$  and  $\text{R}^{13}$  independently represent hydrogen,

$(\text{C}_1\text{-C}_6)\text{alkyl}$  or  $(\text{C}_{6-10})\text{ar}(\text{C}_{1-6})\text{alkyl}$ ; or

one of the combination  $\text{R}^{10}$  and  $\text{R}^{11}$ ,  $\text{R}^{12}$  and  $\text{R}^{13}$  or  $\text{R}^{10}$  and  $\text{R}^{12}$  are taken together to form  $-(\text{CH}_2)_s-$ , wherein s is 1 while the remaining of  $\text{R}^{10}$ - $\text{R}^{13}$  are defined above;


i is 0 or 1;

j is 0 or 1;

k is 0 or 1;

$\text{R}^{14}$  is hydrogen or alkyl;

W is:



wherein:

$\text{R}^{16}$  is hydrogen,  $(\text{C}_{1-8})\text{alkyl}$ ,  $\text{halo}(\text{C}_{1-8})\text{alkyl}$  or halogen; and

$\text{R}^{27}$ ,  $\text{R}^{28}$ , and  $\text{R}^{29}$  are hydrogen, halogen,  $(\text{C}_{1-8})\text{alkyl}$ ,  $(\text{C}_{1-8})\text{alkoxy}$ , or  $(\text{C}_{6-10})\text{aryl}$ .

35. (Original) The compound of claim 1, wherein:

v, m, n, i and j are 0;

a is 1;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup> and R<sup>14</sup> are each hydrogen; and  
R<sup>10</sup> is pyridinyl.

36. (Original) The compound of claim 1, wherein:

v, m, n, i and j are 0;

a is 1;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup> and R<sup>14</sup> are each hydrogen; and  
R<sup>10</sup> is quinolinyl.

37. (Original) The compound of claim 1, wherein:

v, m, n, i and j are 0;

a is 1;

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup> and R<sup>14</sup> are each hydrogen; and  
R<sup>10</sup> is methoxyphenyl.

38. (Previously Presented) The compound of claim 1, which is one of:

3-[5-(2-5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl-acetylamino)-indol-1-yl]-hexanoic acid;

3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-hexanoic acid;

3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-phenyl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-phenyl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-(3-benzyloxy-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-3-p-tolyl-propionic acid;

3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-3-m-tolyl-propionic acid;

3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-3-o-tolyl-propionic acid;

3-biphenyl-4-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-(3,5-dichloro-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-(3,5-difluoro-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-(3-cyano-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-(4-cyano-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-(2-methoxy-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-(3-methoxy-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-(4-methoxy-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-quinolin-3-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-(3-chloro-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-naphthalen-2-yl-3-{5-[2-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-(2-chloro-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-naphthalen-1-yl-3-{5-[2-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-(4-fluoro-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-3-(3-trifluoromethyl-phenyl)-propionic acid;

3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-3-(4-trifluoromethyl-phenyl)-propionic acid;

3-pyridin-3-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-pyridin-2-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-pyridin-4-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-acrylic acid;

3-(2,3-dihydro-benzofuran-5-yl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-benzo[1,3]dioxol-5-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-(5-methanesulfonyl-pyridin-3-yl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-{5-[2-(2-methyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-ethyl]-indol-1-yl}-propionic acid;

3-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-indol-1-yl}-propionic acid;

3-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-indol-1-yl}-hexanoic acid;

3-phenyl-3-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-indol-1-yl}-propionic acid;

3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-3-[5-(2,2,2-trifluoro-ethoxy)-pyridin-3-yl]-propionic acid;

3-(5-ethoxy-pyridin-3-yl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-pyridin-4-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-pyridin-2-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-acrylic acid;

or a pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof.

39. (Previously Presented) The compound of claim 1, which is one of:

3-(3-methoxy-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-quinolin-3-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-pyridin-3-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-pyridin-2-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;


or a pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof.

40. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

41. (Previously Presented) A method of treating a pathological condition selected from the group consisting of osteoporosis, macular degeneration, diabetic retinopathy, rheumatoid arthritis and sickle cell anemia, in a mammal in need of such treatment, comprising administering to said mammal an effective amount of a compound of claim 1.


42. (Canceled)
43. (Original) The method of claim 41, wherein said condition is osteoporosis.
44. (Canceled)
45. (Canceled)
46. (Original) The method of claim 41, wherein said condition is macular degeneration.
47. (Original) The method of claim 41, wherein said condition is diabetic retinopathy.
48. (Original) The method of claim 41, wherein said condition is rheumatoid arthritis.
49. (Original) The method of claim 41, wherein said condition is sickle cell anemia.
50. (Original) A process for preparing a substituted indole compound of claim 1, comprising:

reacting a compound of Formula V:



or a salt, hydrate or solvate thereof, wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $i$  and  $j$  are as defined in claim 1,

with the compound of Formula VI or Formula X:



or a salt, hydrate or solvate thereof, wherein  $R^{15}$ ,  $R^{16}$ ,  $R^{27}$ ,  $R^{28}$  and  $R^{29}$  are as defined in claim 1, to form a substituted indole compound of claim 1.

Claims 51-53 (Canceled)

54. (Currently Amended) A method for treating a central nervous system (CNS) related disorder, selected from the group consisting of: neuronal loss associated with ~~stroke, ischemia, CNS trauma, hypoglycemia, surgery, a neurodegenerative disease, an adverse consequence of overstimulation of one or more excitatory amino acids~~, schizophrenia, anxiety, convulsions, chronic pain, psychosis, ~~anesthesia~~, and opiate tolerance, in a mammal in need of such treatment, comprising administering to said mammal an effective amount of a compound of claim 1.

55. (Currently Amended) The method according to claim 54, wherein said CNS related disorder is neuronal loss associated with ~~stroke~~ ischemia, CNS trauma, hypoglycemia, surgery, or anesthesia.

56. (Original) The method according to claim 54, wherein said CNS related disorder is ischemia.

57. (Original) The method according to claim 54, wherein said CNS related disorder is CNS trauma.

58. (Original) The method according to claim 54, wherein said CNS related disorder is hypoglycemia.



59. (Original) The method according to claim 54, wherein said CNS related disorder is the result of surgery.

60-61. (Canceled)

62. (Original) The method according to claim 54, wherein said CNS related disorder is schizophrenia.

63. (Original) The method according to claim 41, wherein the activity of  $\alpha 4$  integrin is inhibited.

64. (Original) The method according to claim 54, wherein the activity of  $\alpha 4$  integrin is inhibited.

65. (Original) The compound according to claim 17, wherein  $R^{12}$  and  $R^{13}$  are independently selected from:

